If you've started looking into low testosterone, you've likely run into two very different strategies that are sometimes discussed in the same breath. Understanding how they actually work — and where they diverge — can make a conversation with a provider far more productive.
Two different jobs, two different tools
The core distinction is mechanism. Testosterone therapy adds testosterone to the body from an outside source. Enclomiphene doesn't add testosterone at all; instead, it nudges the body's own signaling pathway to make more.
To see why that matters, it helps to picture the chain of command that controls male hormone production. The hypothalamus releases gonadotropin-releasing hormone, which prompts the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH tells the testes to produce testosterone; FSH supports sperm production. The whole system runs on a feedback loop — when testosterone is high enough, the brain dials back its signals [1].
These two approaches act at opposite ends of that loop.
Source: [1] Physiology, Hypothalamic Pituitary Gonadal Axis — StatPearls, NIH National Library of Medicine
How testosterone therapy works
Testosterone therapy (often abbreviated TRT) supplies the hormone directly — through formulations such as injections, gels, or pellets. The Endocrine Society's clinical practice guideline frames it as an option for men who have both consistently low morning testosterone on more than one test *and* symptoms consistent with deficiency [2].
Because the body senses circulating testosterone from any source, supplementing from outside triggers that feedback loop. The brain reduces its LH and FSH output, and the testes' own production tends to quiet down. One well-documented consequence is an effect on fertility: by suppressing the signals that drive sperm production, exogenous testosterone can reduce sperm counts, sometimes substantially. The FDA-approved labeling for testosterone products notes that the therapy may impair fertility [3].
This is the single most important trade-off for many men, particularly those who may want to father children. It's also why providers often ask about family-planning goals early in the conversation.
How enclomiphene works
Enclomiphene takes the opposite route. It is an estrogen receptor modulator — specifically, it occupies estrogen receptors in the hypothalamus and pituitary. The brain interprets this as lower estrogen feedback and responds by increasing its output of LH and FSH. Those signals, in turn, stimulate the testes to produce more of their own testosterone [4].
Enclomiphene is the *trans*-isomer of clomiphene, a compound long studied in reproductive medicine. The distinction matters because researchers have examined enclomiphene's ability to raise testosterone while, in studies to date, generally preserving the LH/FSH signaling that supports sperm production — a different profile from directly supplementing the hormone [4][5].
Because this approach works *through* the body's natural axis rather than overriding it, it is sometimes discussed for men who want to address low testosterone while keeping fertility in mind. That said, individual responses vary, and only an independent provider can determine whether any option is appropriate for a given person.
A regulatory note: enclomiphene is not an FDA-approved standalone product. Where it is offered, it is typically a compounded medication. *Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.*
Source: [3] FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging, [4] Treatment of men for "low testosterone": A systematic review (PLOS ONE; includes enclomiphene mechanism and axis effects)
What providers tend to consider
For either approach, evaluation usually starts before any prescription. The Endocrine Society guideline emphasizes diagnosing testosterone deficiency on the basis of unequivocally low testosterone measured on at least two separate mornings, alongside relevant symptoms — not on symptoms or a single value alone [2].
Common considerations a provider may weigh include:
- Confirmed low levels and symptoms. A diagnosis generally rests on repeat morning lab measurements plus a clinical picture, not numbers in isolation [2].
- Fertility goals. This often shapes the conversation more than any other factor, given the documented effect of exogenous testosterone on sperm production [3].
- Baseline health. Providers typically review cardiovascular history, prostate health, red-blood-cell counts (hematocrit), and other markers. The FDA has communicated about the importance of appropriate use and monitoring for testosterone products [3].
- Underlying cause. Low testosterone can stem from a problem in the testes themselves (primary) or in the brain's signaling (secondary). An approach that relies on stimulating the testes depends on those testes being able to respond [1].
No prescription is ever guaranteed. Whether either approach is suitable — and which, if any — is a decision an independent licensed provider makes after reviewing your individual history and labs.
Monitoring: an ongoing part of either path
Neither approach is "set and forget." With testosterone therapy, monitoring commonly includes periodic testosterone levels, hematocrit (because therapy can raise red-blood-cell counts), and prostate-specific antigen (PSA) where appropriate, on a schedule the provider sets [2]. With approaches that stimulate the natural axis, providers often track testosterone along with LH and FSH to see how the signaling pathway is responding [4].
The point of monitoring is the same in both cases: to keep the strategy aligned with the individual's response and safety over time, and to adjust course if needed.
A quick side-by-side
| | Testosterone therapy | Enclomiphene |
|---|---|---|
| Mechanism | Supplies testosterone from outside the body | Signals the brain to increase the body's own production |
| Effect on the natural axis | Tends to suppress LH/FSH | Works through LH/FSH |
| Fertility consideration | May impair sperm production [3] | Studied for preserving the fertility-supporting signal [4][5] |
| Regulatory status | FDA-approved products exist | Typically compounded; not FDA-approved as a standalone product |
| Typical monitoring | Testosterone, hematocrit, PSA, symptoms [2] | Testosterone, LH, FSH, symptoms [4] |
This comparison is educational and simplified; the right choice depends on the individual, and the table is not a recommendation.
The takeaway
The central difference is direction. Testosterone therapy *replaces* — it adds the hormone and, in doing so, tends to quiet the body's own production, including the signals tied to fertility. Enclomiphene *restarts* — it asks the body's existing machinery to do more, which is why it's often part of conversations where fertility is a priority. Each has trade-offs, each requires ongoing monitoring, and each is appropriate for different people and different goals.
This article is educational and is not medical advice. It is not a diagnosis or a recommendation to use any specific medication. Talk with a licensed provider about your own situation.
Where Velri fits
Velri is a technology and coordination company — it does not provide medical care. What Velri can do is make the process clearer: helping coordinate baseline lab work, connecting you with an independent, licensed provider for an evaluation, and — *if* that provider determines a prescription is appropriate — coordinating fulfillment through an independent, licensed pharmacy. Medical decisions, including whether to prescribe anything at all, rest entirely with the independent provider. Where a compounded medication is involved, remember: compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality, are not equivalent to or interchangeable with any FDA-approved brand-name drug, and availability varies by state.
